APA (7th ed.) Citation

MHG, K., Q, S., J, M., JM, H., M, C., BM, W., . . . EM, O. (2022). Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial. JAMA oncology, 8(9), 1263. https://doi.org/10.1001/jamaoncol.2022.2319

Chicago Style (17th ed.) Citation

MHG, Katz, et al. "Efficacy of Preoperative MFOLFIRINOX Vs MFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial." JAMA Oncology 8, no. 9 (2022): 1263. https://doi.org/10.1001/jamaoncol.2022.2319.

MLA (9th ed.) Citation

MHG, Katz, et al. "Efficacy of Preoperative MFOLFIRINOX Vs MFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial." JAMA Oncology, vol. 8, no. 9, 2022, p. 1263, https://doi.org/10.1001/jamaoncol.2022.2319.